Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation

Cardiac Division, Massachusetts General Hospital, Boston 02114.

The comparative effects of intravenous aspirin, the synthetic thrombin inhibitor (2R,4R)-4-methyl-1-[N2-(3-methyl-1,2,3,4-tetrahydro-8- quinolinesulfonyl)-L-arginyl]-2-piperidinecarboxylic acid monohydrate (Argatroban) and F(ab')2 fragments of monoclonal antibody 7E3 against platelet glycoprotein IIb/IIIa (7E3-F[ab']2) on thrombolysis, reocclusion and bleeding associated with 0.45 mg/kg body weight bolus injections of recombinant tissue-type plasminogen activator (rt-PA) were studied in a canine coronary artery thrombosis model. Coronary patency was monitored for 2 h both by flow probe and by coronary angiography. Four groups were studied: Group I = pretreated with 17 mg/kg intravenous aspirin (n = 6), Group II = pretreated with 200 micrograms/kg per min intravenous Argatroban for 60 min (n = 5), Group III = pretreated with aspirin and Argatroban (n = 5) and Group IV = pretreated with 0.8 mg/kg intravenous 7E3-F(ab')2 (n = 5). In Group I, reflow occurred in four of six dogs, but did not persist; reflow was induced in Group II in four of five dogs, persisting in one; in Group III, reflow occurred in all five dogs, persisting in four; in Group IV reflow was achieved in four of five dogs, persisting in two. The frequency of persistent reflow in Group III was significantly higher than in the combined Groups I and II (p = 0.012), whereas the time to reflow was significantly shorter in the groups receiving Argatroban than in the aspirin group (median 25 versus 55 min, p = 0.04). There were no significant differences between Groups III and IV.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				A. A. Divani, K. Rasmussen, G. Vazquez, and G. H. R. Rao Effect of Blood Soluble Clotting Factors on Coagulation Profile Clinical and Applied Thrombosis/Hemostasis, August 1, 2010; 16(4): 475 - 479. [Abstract] [PDF]

				G. D. Lewis, C. Witzke, P. Colon-Hernandez, J. L. Guerrero, K. D. Bloch, and M. J. Semigran Sildenafil Improves Coronary Artery Patency in a Canine Model of Platelet-Mediated Cyclic Coronary Occlusion After Thrombolysis J. Am. Coll. Cardiol., April 4, 2006; 47(7): 1471 - 1477. [Abstract] [Full Text] [PDF]

				Q. Lian, S. J. Szarka, K. K. S. Ng, and S.-L. Wong Engineering of a Staphylokinase-based Fibrinolytic Agent with Antithrombotic Activity and Targeting Capability toward Thrombin-rich Fibrin and Plasma Clots J. Biol. Chem., July 11, 2003; 278(29): 26677 - 26686. [Abstract] [Full Text] [PDF]

				U. Schmidt, R. O. Han, T. G. DiSalvo, J. L. Guerrero, H. K. Gold, W. M. Zapol, K. D. Bloch, and M. J. Semigran Cessation of platelet-mediated cyclic canine coronary occlusion after thrombolysis by combining nitric oxide inhalation with phosphodiesterase-5 inhibition J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1981 - 1988. [Abstract] [Full Text] [PDF]

				P. Monagle, A. D. Michelson, E. Bovill, and M. Andrew Antithrombotic Therapy in Children Chest, January 1, 2001; 119(2009): 344S - 370S. [Full Text] [PDF]

				C. V. Jackson, B. D. Bailey, and T. J. Shetler Pharmacological Profile of Recombinant, Human Activated Protein C (LY203638) in a Canine Model of Coronary Artery Thrombosis J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 967 - 971. [Abstract] [Full Text]

				M. M. Bednar and C. E. Gross Antiplatelet Therapy in Acute Cerebral Ischemia Stroke, April 1, 1999; 30(4): 887 - 893. [Abstract] [Full Text] [PDF]

				S. A. Mousa, J. M. Bozarth, W. Lorelli, M. S. Forsythe, M. J. M. C. Thoolen, A. M. Slee, T. M. Reilly, and P. A. Friedman Antiplatelet Efficacy of XV459, A Novel Nonpeptide Platelet GPIIb/IIIa Antagonist: Comparative Platelet Binding Profiles with c7E3 J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1277 - 1284. [Abstract] [Full Text]

				S. A. Mousa, D.-X. Mu, and B. R. Lucchesi Prevention of Carotid Artery Thrombosis by Oral Platelet GPIIb/IIIa Antagonist in Dogs Stroke, April 1, 1997; 28(4): 830 - 836. [Abstract] [Full Text]

				R. P. Schwarz JR, J.-C. P. Becker, R. L. Brooks, M. J. Hursting, J. L. Joffrion, G. D. Knappenberger, T. P. Kogan, P. W. Kogan, and A. A. McKinney State-of-the-Art Review: The Preclinical and Clinical Pharmacology of Novastan (Argatroban): A Small-Molecule, Direct Thrombin Inhibitor Clinical and Applied Thrombosis/Hemostasis, January 1, 1997; 3(1): 1 - 15. [Abstract] [PDF]

				C. Adrie, K. D. Bloch, P. R. Moreno, W. E. Hurford, J. L. Guerrero, R. Holt, W. M. Zapol, H. K. Gold, and M. J. Semigran Inhaled Nitric Oxide Increases Coronary Artery Patency After Thrombolysis Circulation, October 15, 1996; 94(8): 1919 - 1926. [Abstract] [Full Text]

				C. V. Jackson, J. Satterwhite, and E. Roberts Preclinical and Clinical Pharmacology of Efegatran (LY294468) : A Novel Antithrombin for the Treatment of Acute Coronary Syndromes Clinical and Applied Thrombosis/Hemostasis, October 1, 1996; 2(4): 258 - 267. [Abstract] [PDF]

				D. R. Abendschein, Y. Y. Meng, S. Torr-Brown, and B. E. Sobel Maintenance of Coronary Patency After Fibrinolysis With Tissue Factor Pathway Inhibitor Circulation, August 15, 1995; 92(4): 944 - 949. [Abstract] [Full Text]

				N. A. Prager, D. R. Abendschein, C. R. McKenzie, and P. R. Eisenberg Role of Thrombin Compared With Factor Xa in the Procoagulant Activity of Whole Blood Clots Circulation, August 15, 1995; 92(4): 962 - 967. [Abstract] [Full Text]

				D. D. Callas, O. Iqbal, D. Hoppensteadt, and J. Fareed Fibrinolytic Compromise by Synthetic and Recombinant Thrombin Inhibitors: Implications in the Treatment of Thrombotic Disorders Clinical and Applied Thrombosis/Hemostasis, March 1, 1995; 1(2): 114 - 124. [Abstract] [PDF]

				J. Strony, A. Song, L. Rusterholtz, and B. Adelman Aurintricarboxylic Acid Prevents Acute Rethrombosis in a Canine Model of Arterial Thrombosis Arterioscler Thromb Vasc Biol, March 1, 1995; 15(3): 359 - 366. [Abstract] [Full Text]

				A. T. Gentile, T. G. DeLoughery, and J. M. Porter Novel Antithrombotic Agents in Vascular Surgery Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1994; 7(2): 57 - 72. [PDF]